Abbott Laboratories ABT recently received FDA approval for its Eterna spinal cord stimulation (SCS) system for treating chronic pain. The Eterna SCS system is the smallest implantable, rechargeable ...

Abbott ABT recently announced the first usage of its Eterna spinal cord stimulator (SCS) system in Canada. This marks a significant milestone in the company’s approach to chronic pain management. The ...

Abbott has obtained FDA clearance of its Eterna spinal cord stimulation (SCS) system for the treatment of chronic pain. The system is the smallest implantable, rechargeable SCS — thin wires placed ...

Please provide your email address to receive an email when new articles are posted on . Expanded labeling allows those with chronic pain to have a wider selection of leads for full-body scans. Eterna ...

The US Food and Drug Administration (FDA) has approved expanded MRI labeling for Abbott Laboratories' Eterna spinal cord stimulation (SCS) system, which will allow for higher-quality scan images for ...

Abbott Laboratories (NYSE:ABT) announced Thursday that the FDA approved expanded MRI labeling for its pain relief device Eterna spinal cord stimulation (SCS) system, allowing its use in patients who ...

Abbott developed Eterna based on extensive studies with patients, physicians and caregivers to understand the unmet needs of people living with chronic pain. The studies found that people wanted a ...

Building on the U.S. FDA approval of its Proclaim Plus spinal cord stimulation (SCS) system in August, Abbott Laboratories notched another approval with the FDA’s greenlight of the Eterna spinal cord ...

Abbott announced new five-year data demonstrating that its neuromodulation therapies, including its proprietary BurstDR spinal cord stimulation (SCS) waveform and dorsal root ganglion stimulation ...